^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4343 Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis
Published date:
11/03/2022
Excerpt:
The aim of this study is to describe “real-world” treatment patterns, clinical outcomes, and adverse events (AEs) in CML-CP patients receiving 3 or more lines of therapy (3L+) and those with the ABL1 T315I mutation….In 145 patients with documented responses in 3L, the rate of achieving MMR, MR4.0, and MR4.5 at 12 months was 42%, 27%, and 14%, respectively....
DOI:
https://doi.org/10.1182/blood-2022-160268 Split-Screen Share Icon Share Tools Icon Tool
